Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Phase 3positiveEnhertuPositive
AI Analysis
Summary
Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as a first-line treatment for HER2 mutant advanced non-small cell lung cancer in the Phase 3 DESTINY-Lung04 trial.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Statistically significant and clinically meaningful improvement in progression-free survival as first-line treatment
Importance:8/10
Sentiment:
0.85
EnhertuHER2 mutantNSCLCDESTINY-Lung04Phase 3PFS
Related Companies
Read the original article
Published by yahoo_finance on August 17, 2026 6:30 AM